Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
Pooled result · Weight changeResult — go to the resultMean difference −4.21 kg 95% CI −7.08 to −1.35Authors' conclusion
The evidence suggests that GLP-1RAs reduce most weight-related outcomes in adolescents, with semaglutide being the most efficacious. There is uncertain evidence on body fat and serious AEs, probably due to fewer studies and low incidence, respectively. Larger RCTs with head-to-head comparisons, pragmatic design, adiposity-related outcomes, and economic evaluation can further guide the use and choice of GLP-1RAs.
Study context
- Population
- Adolescents with overweight or obesity, with or without T2D; 5 databases and registries searched until 2 March 2024
- Participants
- 883 adolescents12 randomized controlled trials (RCTs)
- Comparison
- GLP-1 RAs vs placebo; GLP-1 RAs vs each other
- Outcome
- Weight change
Methodological detailspairwise meta-analysis, drug-wise network meta-analysis
- Pairwise meta-analysis
- Drug-wise network meta-analysis
Pooled result
As reported in the abstract
Mean difference
−4.21 kg
95% CI −7.08 to −1.35
GLP-1RAsvs Placebo
mean difference −4.21 kg (95% CI −7.08 to −1.35)
Further pooled results
| Outcome | Mean difference (kg/m²) (95% CI) | |
|---|---|---|
| BMI | −2.11 (−3.60 to −0.62) | |
| −4−202Difference, kg/m² (linear scale) |
Waist circumference and body fat percentage
- Evidence very uncertain
Subgroups by coexisting T2D
- Results remained consistent
Therapy duration
- Longer therapy duration led to greater reduction in weight and body mass index (BMI)
Weight reduction ranking (network meta-analysis (NMA))
- Semaglutide led to the greatest weight reduction, followed by exenatide, liraglutide and lixisenatide
Safety
Adverse events
- Evidence on adverse events (AEs) very uncertain
Original publication
Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis. Diabetes Obes Metab. Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →